Xencor Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Xencor Inc's ROI in the second quarter of 2026?
Xencor Inc recorded a cumulative net loss of $-163 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -22.78%.

Within the Healthcare sector 327 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2037 to 3390.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-15.12 %	-10.44 %	-6.15 %	-4.71 %	4.44 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	643	663	780	782	783
Return On Investment (TTM)	-22.78 %	-22.92 %	-11.66 %	-16.18 %	-20.35 %
XNCR's Overall Ranking	# 3390	# 2037	# 2521	# 3048	# 2986
Seq. Investment Change TTM	-4.66 %	-4.84 %	-2.89 %	-3.66 %	0.6 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-163	-172	-92	-132	-172

XNCR Company Profile >> Back to XNCR Roi Comparisons >> See Annual XNCR Return On Investment

Return On Investment XNCR's Ranking
Within:	No.
Industry	# 121
Sector	# 328
Overall	# 3390

Return On Investment Statistics
High	Average	Low
22.11 %	-7.98 %	-27.95 %
(Jun 30 2016)		(Dec 31 2024)

News about Xencor Inc Return on Investment ROI

Xencor Advances Corporate Strategy with Addition of Dane Leone as Senior Vice President

January 2, 2024

Xencor, a leading clinical-stage biopharmaceutical company specializing in engineered antibodies and cytokines, announced in a recent press release that Dane Leone, a seasoned financial expert, has joined the firm as the senior vice president of corporate strategy. This strategic appointment will bolster Xencor s ongoing efforts in enhancing its platform technologies and maximizing value across its revolutionary cancer and autoimmune disease treatments.
Dane Leone s Role at Xencor:
In his newly created position, Mr. Leone will collaborate closely with Xencor s research and development (RandD) leadership team. His primary responsibility will be to drive value optimization initiatives by overseeing the assessment and prioritization of the company s current and future endeavors, primarily focusing on its Xenco platform. With his extensive experience and expertise as a Chartered Financial Analyst (CFA), Mr. Leone will leverage his strategic vision to ensure Xencor remains at the forefront of cutting-edge biopharmaceutical innovations.

Financial Statements
Xencor Inc's II. Quarter Investments	$ 643 Millions	XNCR's Balance sheet
Xencor Inc's II. Quarter Income	$ -22 Millions	Quarterly XNCR's Income Statement
XNCR's Income by Division		See XNCR's Income by Division

XNCR Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	780	854	892	782	767
Y / Y Investment Growth	-8.71 %	-4.22 %	13.95 %	1.95 %	31.83 %
Net Income in Millions	-92	-237	-133	-55	83
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-11.82 %	-27.7 %	-14.95 %	-7.05 %	10.77 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
XNCR's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for XNCR's Competitors
Subscribers only: Roi for Xencor Inc's Suppliers
Subscribers only: Return On Investment for XNCR's Customers

Other Ratios
XNCR's Roa	XNCR's Inventory Turnover Ratio	XNCR's Growth Rates	XNCR's Dividend Statistics
	XNCR's Profitability Ratios	XNCR's Asset Turnover Ratio	XNCR's Dividend Growth
XNCR's Roe	XNCR's Valuation Ratios	XNCR's Financial Strength Ratios	XNCR's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-10T01:30:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.